Körber’s Post

The end of the last decade brought record highs in pharmaceutical M&A as larger companies turned again and again to young biotechs for innovation. That trend is on the upswing again. Here are the latest deals: https://ow.ly/ljjs30sFwzE #manda #biopharma #drugdevelopment #biotech #mergersandacquisitions

A great move for Franz Ziel and Körber - combining forces and strengthening the bond between two partners. It was a pleasure working with the awesome collegues at Franz Ziel, Körber Business Area Pharma and of course the Körber Group Team as well as our external advisors. #wearekörber #strongertogether #manda #pharma #franzziel #protectinglifewithtechnology

Why Summits is excited for our upcoming 23rd Pharma & BioTech PPM Conference being held in Boston, Ma (Oct. 16, 17, 18). Please contact me or Simona Marčeková to discuss attending or speaking at this event. #PPM #Pharma #Conference #ProjectManagement

🚀 Launching a new #orphandrug in Europe? The European expansion can be daunting due to the complexities of language, local rules and regulations.  Biotech and pharmaceutical companies have various options to enter the market, but the success of commercialization depends on making choices that match long-term plans and ambitions.   Download our guide to learn how more about ways to navigate the complex European landscape, including takeaways on: 👉 The different approaches you can take (out-licensing, going-it alone, partnering) 👉 The pros and cons of each approach 👉 What to look for in a potential European partner   https://lnkd.in/eb5QG7mU #Biotech #RareDiseases #SciensusSolutions #PatientAccess

The end of the last decade brought record highs in pharmaceutical M&A as larger companies turned again and again to young biotechs for innovation. That trend is on the upswing again. Here are the latest deals: https://ow.ly/KPAM30sFxVN #manda #biopharma #drugdevelopment #biotech #mergersandacquisitions

Antheia, Inc. and Olon Continue #Biomanufacturing Partnership US #biotech company Antheia and Olon, an Italian producer of active #pharmaceutical ingredients (APIs), have announced the continuation of their ongoing partnership to utilize Olon’s #fermentation infrastructure for the scale-up and commercialization of Antheia’s early products. The two companies established this partnership in 2022, and Olon has since served as a contract development and manufacturing organization (CDMO) for the scale-up of Antheia’s biomanufacturing processes and the production of its biosynthetic key starting materials and #APIs. Looking to 2024 and beyond, Antheia said that it will continue to partner with Olon to unlock additional capacity to meet international demand for its products. According to Antheia, Olon’s global infrastructure and industry expertise were instrumental to Antheia’s recent commercial milestones for its first product, thebaine. Read more on #CMI online: https://lnkd.in/enG5iK26

In this blog, two MMIT solution consultants share four steps smaller pharma companies and biotechs can take to ensure commercialization success—even with limited resources. What exactly does it mean to get an early start on commercialization? MMIT’s Ryan Witherington and Olga Yaremchuk explain what smaller pharma companies should do in Phase I or II to set the stage for market entry: https://ow.ly/cMKv50RovZQ #BiotechTips #PharmaSolutions #MarketEntry #PharmaInsights #PharmaConsulting #BiotechStrategy

When biotech and biopharma firms seek a CDMO for drug development and/or manufacturing, price is the second most important consideration behind the combination of technical fit, capabilities that match the project, and track record. However, getting a complete answer on CDMO pricing and what exactly the stated figures cover – allowing for true ‘apples-to-apples’ comparisons between vendors – is difficult. No standard guides how biotech/biopharma firms should prepare their requests for proposal (RFPs), nor does a standard guide how CDMO proposals are prepared and presented. Read the full article by Vladas Algirdas Bumelis at Northway Biotech https://lnkd.in/ei3dz8Gs #biotech #biopharma 💊

🌐 Exciting times at Bonafi! We're featured in the Business Post, highlighting our journey and ambitions for international expansion. This article gives an insight into how we're setting new standards in pharmaceutical compliance and our plans for growing our team in Meath. Read about our journey and future goals here. Contact us for further information. #Bonafi #PharmaceuticalCompliance #PharmaInnovation #LifeSciences #IrishTech #StartupGrowth

Here are four tips for smaller manufacturers on how you might approach the journey to commercialization—and come out ahead, despite the obstacles.